Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach

Sainz de la Maza, Susana ; Gómez-Ballesteros, Rocío ; Borges, Mónica ; Martín-Martínez, Jesús ; Sotoca, Javier ; Alonso, Ana ; Caminero, Ana B. ; Borrega, Laura ; Sánchez-Menoyo, José L. ; Barrero-Hernández, Francisco J. ; Calles, Carmen ; Brieva, Luis ; Blasco-Quílez, María R. ; Dotor García-Soto, Julio ; Campo-Amigo, María del ; Navarro-Cantó, Laura ; Agüera, Eduardo ; Garcés-Redondo, Moisés (Universidad de Zaragoza) ; Carmona, Olga ; Gabaldón-Torres, Laura ; Forero, Lucía ; Hervàs, Mariona ; Medrano, Nicolás ; Maurino, Jorge ; Castillo-Triviño, Tamara

Resumen: Disability accrual is mainly driven by progression independent of relapse activity, which is present even in early stages of relapsing-remitting multiple sclerosis (RRMS) and sometimes overlooked. This multicenter, non-interventional study evaluated whether patient-reported outcomes measures (PROMs) could capture disability in 189 early-stage RRMS patients (mean age: 36.1 ± 9.4 years, 71.4% female, mean disease duration: 1.4 ± 0.8 years, median EDSS: 1.0). The 9-Hole Peg Test (9-HPT), NeuroQoL Upper Extremity (NeuroQoL-UE), Timed 25-Foot Walk (T25-FW), Multiple Sclerosis Walking Scale (MSWS-12), Symbol Digit Modalities Test (SDMT), and Perceived Deficits Questionnaire (PDQ-5) were used to assess hand function, gait, and cognition, respectively. These functions were at least mildly affected in this early-stage population, finding significant correlations between PROMs and clinical assessments. PROMs could enable early-stage RRMS patients to communicate their perceived disability in different domains, assisting clinicians in disease monitoring and decision making.

Idioma: Inglés

DOI: 10.1177/20552173231169475

Año: 2023

Publicado en: Multiple Sclerosis Journal - Experimental, Translational and Clinical 9, 2 (2023), [7 pp.]
ISSN: 2055-2173

Factor impacto CITESCORE: 4.7 - Neurology (clinical) (Q2) - Cellular and Molecular Neuroscience (Q3)

Factor impacto SCIMAGO: 0.959 - Neurology (clinical) (Q2) - Cellular and Molecular Neuroscience (Q3)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)